Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 30.10.2017 | EN | Official Journal of the European Union | C 369/12 |

---

Judgment of the General Court of 15 September 2017 — Viridis Pharmaceutical v EUIPO — Hecht-Pharma (Boswelan)

(Case T-276/16)[(1)](#ntr1-C_2017369EN.01001201-E0001)

((EU trade mark - Revocation proceedings - EU word mark Boswelan - Declaration of revocation - Article 51(1)(a) of Regulation (EC) No 207/2009 - No genuine use of the trade mark - No proper reasons for non-use))

(2017/C 369/16)

Language of the case: German

Parties

Applicant: Viridis Pharmaceutical Ltd (Tortola, British Virgin Isles) (represented by: C. Spintig, S. Pietzcker and M. Prasse, lawyers)

Defendant: European Union Intellectual Property Office (represented by: S. Hanne, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Hecht-Pharma GmbH (Hollnseth, Germany) (represented by: C. Sachs and J. Sachs, lawyers)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 29 February 2016 (Case R 2837/2014-5), relating to revocation proceedings between Hecht-Pharma and Viridis Pharmaceutical.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Viridis Pharmaceutical Ltd to pay the costs. |

---

[Top](#document1)